1198937_Harris,M_2022.pdf (919 kB)
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
journal contributionposted on 2022-05-10, 01:50 authored by Michael HarrisMichael Harris, Christine HawkinsChristine Hawkins
The survival rate for metastatic osteosarcoma has not improved for several decades, since the introduction and refinement of chemotherapy as a treatment in addition to surgery. Over two thirds of metastatic osteosarcoma patients, many of whom are children or adolescents, fail to exhibit durable responses and succumb to their disease. Concerted efforts have been made to increase survival rates through identification of candidate therapies via animal studies and early phase trials of novel treatments, but unfortunately, this work has produced negligible improvements to the survival rate for metastatic osteosarcoma patients. This review summarizes data from clinical trials of metastatic osteosarcoma therapies as well as pre-clinical studies that report efficacy of novel drugs against metastatic osteosarcoma in vivo. Considerations regarding the design of animal studies and clinical trials to improve survival outcomes for metastatic osteosarcoma patients are also discussed.
This research was funded by The Kids' Cancer Project, Cancer Council Victoria (grant number 1145995) and Tour De Cure. The APC was funded by La Trobe University.
JournalInternational Journal of Molecular Sciences
Article NumberARTN 3817
Rights Statement© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Science & TechnologyLife Sciences & BiomedicinePhysical SciencesBiochemistry & Molecular BiologyChemistry, MultidisciplinaryChemistryosteosarcomametastasismetastasessarcomatyrosine kinase inhibitorsimmunotherapyanimal modelsprogression free survivalcancermetastaticPHASE-II TRIALPEDIATRIC-ONCOLOGY-GROUPLIPOSOMAL MURAMYL TRIPEPTIDEINHIBITS LUNG METASTASISHIGH-GRADE OSTEOSARCOMAHIGH-DOSE CHEMOTHERAPYSOFT-TISSUE SARCOMASTEM-CELL RESCUEGROWTH-FACTOR-IL-MTP-PEAdolescentAnimalsBone NeoplasmsHumansLongitudinal StudiesNeoplasms, Second PrimaryOsteosarcomaChemical PhysicsGeneticsBiological Sciences not elsewhere classifiedChemical Sciences not elsewhere classified